Clinical Trials Browser

Phase 3 × INDUSTRY × Thoracic × Clear all

NCT03043872 2026-04-22

CASPIAN

Phase 3 Active not recruiting

987 enrolled 42 charts 1 FDA

Small Cell Lung Carcinoma

NCT04487080 2026-04-22

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-04-22

MARIPOSA-2

Phase 3 Active not recruiting

776 enrolled 13 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05687266 2026-04-22

AVANZAR

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06077760 2026-04-22

INTerpath-002

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07099898 2026-04-22

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

Phase 3 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02296125 2026-04-21

FLAURA

Phase 3 Completed

674 enrolled 21 charts 1 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT03710876 2026-04-21

INFINITE

Phase 3 Completed

53 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT04765059 2026-04-21

COMPEL

Phase 3 Active not recruiting

98 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT05132075 2026-04-21

KontRASt-02

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06311721 2026-04-21

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT06646276 2026-04-21

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Phase 3 Recruiting

Small Cell Lung Carcinoma

NCT06992609 2026-04-21

ALBORAN

Phase 3 Recruiting

Small Cell Lung Carcinoma

NCT07144280 2026-04-21

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07541170 2026-04-21

KRASCENDO 3

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05920356 2026-04-20

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06119581 2026-04-20

SUNRAY-01

Phase 3 Recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06497556 2026-04-20

Krascendo 1

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06623422 2026-04-20

INTerpath-009

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06758401 2026-04-20

Be6A Lung-02

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06838273 2026-04-20

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06890598 2026-04-20

SUNRAY-02

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07190248 2026-04-20

KANDLELIT-007

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07222566 2026-04-20

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT07416474 2026-04-20

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07431827 2026-04-20

KANDLELIT-013

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07472517 2026-04-20

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Phase 3 Recruiting

Small Cell Lung Carcinoma

NCT07502300 2026-04-20

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT06312137 2026-04-17

TroFuse-019

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06382116 2026-04-17

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06382129 2026-04-17

A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06452277 2026-04-17

SOHO-02

Phase 3 Recruiting

Advanced Non-small Cell Lung Cancer

NCT06500026 2026-04-17

A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)

Phase 3 Active not recruiting

Small Cell Lung Carcinoma

NCT05317858 2026-04-16

LIMITLESS

Phase 3 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05450692 2026-04-16

LATIFY

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07005128 2026-04-16

DeLLphi-312

Phase 3 Recruiting

Small Cell Lung Carcinoma

NCT07185997 2026-04-16

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Phase 3 Recruiting

Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms

NCT01630733 2026-04-15

ENSPIRIT

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT03520686 2026-04-15

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3 Terminated

Carcinoma, Non-Small-Cell Lung

NCT06117774 2026-04-15

DeLLphi-306

Phase 3 Recruiting

Small Cell Lung Carcinoma

NCT06151574 2026-04-15

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase 3 Active not recruiting

Lung Neoplasms

NCT06745908 2026-04-15

ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07361510 2026-04-15

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04928846 2026-04-14

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05671510 2026-04-14

PRESERVE-003

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07154706 2026-04-14

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07183189 2026-04-14

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04538664 2026-04-13

PAPILLON

Phase 3 Active not recruiting

308 enrolled 12 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05388669 2026-04-13

PALOMA-3

Phase 3 Active not recruiting

418 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT06170788 2026-04-13

TroFuse-007

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung